Go Deep
Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 15,950 | -2.0 | 15.28 | 0.42 | 363.65 |
| Oct 2026 | 16,075 | -2.0 | 15.08 | 0.42 | 358.95 |
| Oct 2026 | 16,538 | -2.1 | 14.34 | 0.42 | 340.50 |
| Oct 2026 | 16,926 | -2.0 | 13.72 | 0.42 | 326.17 |
| Oct 2026 | 16,851 | -2.0 | 13.84 | 0.42 | 329.01 |
| Oct 2026 | 16,450 | -2.1 | 14.48 | 0.42 | 343.33 |
| Oct 2026 | 15,949 | -2.2 | 15.28 | 0.42 | 361.52 |
| Oct 2026 | 16,701 | -2.0 | 14.08 | 0.42 | 334.58 |
Verrica Pharmaceuticals Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 5,862,000.0 | 5,023,000.0 | 5,092,000.0 | 14,344,000.0 |
| Net Profit | -13,153,000.0 | -9,682,000.0 | -8,074,000.0 | -274,000.0 |
| EPS | -0.6 | -0.5 | -0.6 | -0.0 |
Verrica Pharmaceuticals Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 35,577,000.0 | 7,566,000.0 | 5,124,000.0 | 9,032,000.0 | — |
| Net Profit | -17,886,000.0 | -76,579,000.0 | -66,995,000.0 | -24,487,000.0 | — |
| EPS | -1.7 | -14.8 | -14.8 | -7.2 | — |
Verrica Pharmaceuticals Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 47,131,000.0 | 54,134,000.0 | 81,597,000.0 | 44,721,000.0 | — |
| Total Liabilities | 22,388,000.0 | 63,994,000.0 | 61,834,000.0 | 4,688,000.0 | — |
| Total Equity | 24,743,000.0 | -9,860,000.0 | 19,763,000.0 | 40,033,000.0 | — |
Owes vs Owns
Verrica Pharmaceuticals Inc. owed $0.88 for every $1 it owned in Jun 2026, up from $0.10 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.88× | 0.48× | 1.18× | 0.76× | 0.10× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Verrica Pharmaceuticals Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 64.0%Receivables 11.5%Inventory 4.7%Fixed assets (tangible) 4.0%Other assets 15.9%
How it's funded — Dec 2025
Short-term debt 1.6%Long-term debt 1.9%Payables 4.4%Other liabilities 39.6%Shareholders' equity 52.5%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 30.1 | 46.3 | 69.5 | 34.3 |
| Receivables | 5.4 | 0.1 | 4.4 | 0.5 |
| Inventory | 2.2 | 2.5 | 1.0 | 0.0 |
| Fixed assets (tangible) | 1.9 | 2.6 | 3.6 | 5.3 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 7.5 | 2.7 | 3.0 | 4.6 |
| Liabilities & equity | ||||
| Short-term debt | 0.7 | 12.9 | 0.7 | 0.3 |
| Long-term debt | 0.9 | 31.0 | 42.9 | 1.2 |
| Payables | 2.1 | 1.9 | 2.5 | 0.5 |
| Other liabilities | 18.7 | 18.2 | 15.8 | 2.7 |
| Shareholders' equity | 24.7 | -9.9 | 19.8 | 40.0 |
| Net tangible assets | 24.7 | -9.9 | 19.8 | 40.0 |
Verrica Pharmaceuticals Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -17,627,000.0 | -60,927,000.0 | -38,577,000.0 | -18,650,000.0 | — |
| Investing Activities | 0.0 | -19,000.0 | -362,000.0 | 54,041,000.0 | — |
| Financing Activities | 1,445,000.0 | 37,728,000.0 | 74,213,000.0 | -16,870,000.0 | — |